Xiaojun Max Xu

Principal Computational Biologist at Genesis Molecular AI

Role: Principal Scientist at Genesis Molecular AI
Location: San Diego, CA, US
LinkedIn followers: 500 followers

About Xiaojun Max Xu

Experienced computational scientist with a demonstrated history of working in the health care and pharma industry. Skilled in Multi-Omics data analysis, Molecular Modeling, applying AI/ML algorithms in precision medicine, R, Python, and Shell Scripting.

Experience

Principal Scientist
Genesis Molecular AI
Aug 2024 — Present · San Diego, CA, US

Education

Georgia State University
Doctor of Philosophy (Ph.D.), Computational Chemistry
2008 — 2014
Georgia State University
Master's Degree, Computer Science
2012 — 2014
Hefei University
Bachelor’s Degree, Bioengineering
2000 — 2004
University of Science and Technology of China
Certificate of Completion (Master program), Cell/Cellular and Molecular Biology
2005 — 2008

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@genesistherapeutics.ai
Personal email
•••••@•••••.com
Direct dial
+14•••••••16

Unlock verified contacts

Free to start · No credit card required

Current company

Genesis Molecular AI

Biotechnology Research · 168 employees · Burlingame, California, United States

Genesis Molecular AI – headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego and offices in New York – is pioneering foundation models for molecular AI to unlock a new era of drug design and development. We are using a proprietary state-of-the-art generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery. The GEMS platform integrates AI and physics into industry-leading models to generate and optimize drug molecules, including the breakthrough generative diffusion model Pearl for structure prediction. GEMS accelerates hit ID through lead optimization and candidate selection by generating promising molecules for synthesis and experimental testing, and iterating this process through cycles of AI-enabled discovery and optimization. We have leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has signed AI platform collaborations across a range of therapeutic areas including Gilead (2024), and Incyte (2025). Genesis has raised over $300M in funding from top AI, technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. To learn more about Genesis Molecular AI, or current employment opportunities, please visit our website.

genesistherapeutics.ai

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About Xiaojun Max Xu

Experience

Principal Scientist

Education

Georgia State University

Georgia State University

Hefei University

University of Science and Technology of China

Find verified contacts for anyone on LinkedIn